Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02890069 · ClinicalTrials.gov registry record · Phase 1
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
A Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT02890069: Completed Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals.
NCT02890069 is a Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 298 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (397% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02890069, a Phase 1 study of Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Primary Outcome
During the first two cycles Cycle = 28 days
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Panobinostat
- BIOLOGICAL PDR001
- DRUG LCL161
- DRUG QBM076
Study Locations (20)
Other
- Novartis Investigative Site - Jena
- Novartis Investigative Site - Ulm
- Novartis Investigative Site - Würzburg
- Novartis Investigative Site - Amsterdam
- Novartis Investigative Site - Leiden
- Novartis Investigative Site - Rotterdam
- Novartis Investigative Site - Utrecht
- Novartis Investigative Site - Seoul
Texas
- University of Texas MD Anderson Cancer Center - Houston
- UT Health San Antonio Mays Cancer Center - San Antonio
California
- UCLA Santa Monica Hematology / Oncology SC - Santa Monica
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- The Regents of the University of Michigan - Ann Arbor
Missouri
- Washington University Medical School SC - St Louis
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 1 |
What the finished NCT02890069 record still lists
NCT02890069 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (397% higher).
The record links to 1 condition, with Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Everolimus is the first listed.
NCT02890069 names 20 study sites across 12 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02890069 about?
NCT02890069 is a clinical study titled "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat". The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
What is the current status of trial NCT02890069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 298 participants. The study started on 2016-10-14. Estimated completion is 2022-02-22.
What conditions does trial NCT02890069 study?
This clinical trial studies the following conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma.
What interventions are being tested in trial NCT02890069?
The interventions under investigation include: Everolimus (DRUG), Panobinostat (DRUG), PDR001 (BIOLOGICAL), LCL161 (DRUG), QBM076 (DRUG).
Who is sponsoring clinical trial NCT02890069?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02890069 being conducted?
This trial has 20 study locations across California, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02890069's enrollment target sits among peer trials
298 134th of 2000 higher than 1,866 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
- NCT06780111 · 298 participants · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- NCT07209358 · 298 participants · NA
EDX110 Randomized Control Trial for Treatment of DFUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI